D F Waterhouse1, A M McLaughlin, F Sheehan, D O'Shea. 1. Department of Endocrinology and Metabolism, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland. Deirdrewaterhouse@ireland.com
Abstract
OBJECTIVES: To investigate the prevalence of ATPIII- and IDF-defined metabolic syndrome (MetS) in an Irish screening population and to determine the calculated cardiovascular risk for each group. DESIGN: A total of 1,716 subjects were enrolled over a 12-month period. MAIN OUTCOMES: The ATPIII-defined prevalence of MetS in this population was 13.2%. Using IDF criteria, 21.4% of subjects were identified as having the MetS. Correlation between the two definitions was high; however, IDF criteria identified an additional 9.5% (n = 164) of the population as having MetS, which ATPIII criteria failed to recognise. CONCLUSION: We noted a higher prevalence of MetS in the studied population when defined by IDF criteria. However, those identified by IDF and not by ATPIII definition did not have a higher cardiovascular risk score by either Framingham or European Score than those without MetS. Thus, application of the ATPIII definition of MetS, may be the more practical.
OBJECTIVES: To investigate the prevalence of ATPIII- and IDF-defined metabolic syndrome (MetS) in an Irish screening population and to determine the calculated cardiovascular risk for each group. DESIGN: A total of 1,716 subjects were enrolled over a 12-month period. MAIN OUTCOMES: The ATPIII-defined prevalence of MetS in this population was 13.2%. Using IDF criteria, 21.4% of subjects were identified as having the MetS. Correlation between the two definitions was high; however, IDF criteria identified an additional 9.5% (n = 164) of the population as having MetS, which ATPIII criteria failed to recognise. CONCLUSION: We noted a higher prevalence of MetS in the studied population when defined by IDF criteria. However, those identified by IDF and not by ATPIII definition did not have a higher cardiovascular risk score by either Framingham or European Score than those without MetS. Thus, application of the ATPIII definition of MetS, may be the more practical.
Authors: Carlos Lorenzo; Manuel Serrano-Ríos; María T Martínez-Larrad; José L González-Sánchez; Segundo Seclén; Arturo Villena; Clicerio Gonzalez-Villalpando; Ken Williams; Steven M Haffner Journal: Diabetes Care Date: 2006-03 Impact factor: 19.112
Authors: Michael P Stern; Ken Williams; Clicerio González-Villalpando; Kelly J Hunt; Steven M Haffner Journal: Diabetes Care Date: 2004-11 Impact factor: 19.112
Authors: Gerd Assmann; Rudy Guerra; Garrett Fox; Paul Cullen; Helmut Schulte; DuWayne Willett; Scott M Grundy Journal: Am J Cardiol Date: 2007-01-02 Impact factor: 2.778
Authors: Kevin McCarthy; Eamon Laird; Aisling M O'Halloran; Padraic Fallon; Deirdre O'Connor; Román Romero Ortuño; Rose Anne Kenny Journal: PLoS One Date: 2022-09-14 Impact factor: 3.752
Authors: Ma Kaykhaei; M Hashemi; B Narouie; A Shikhzadeh; M Jahantigh; E Shirzaei; B Rezazehi; M Hoseinian; S Yousefi; S Masoudian; A Emamdadi; Sf Alavi; R Mashhadi; H Ansari Journal: Iran J Public Health Date: 2012-02-29 Impact factor: 1.429
Authors: Elsi Haverinen; Mariana F Fernandez; Vicente Mustieles; Hanna Tolonen Journal: Int J Environ Res Public Health Date: 2021-12-10 Impact factor: 3.390
Authors: Elsi Haverinen; Laura Paalanen; Luigi Palmieri; Alicia Padron-Monedero; Isabel Noguer-Zambrano; Rodrigo Sarmiento Suárez; Hanna Tolonen Journal: Arch Public Health Date: 2021-12-23